Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants
作者:Jinming Zhou、Guoyan Geng、Jian Hui Wu
DOI:10.1007/s10637-009-9251-7
日期:2010.6
A crucial event in prostate cancer progression is the transition from a hormone-sensitive to a lethal castration-refractory disease state. The antagonist-to-agonist conversion due to mutation in AR is a critical problem with the current clinically used antiandrogens. We aim to identify novel antiandrogens that remain as a pure antagonist even in the mutated ARs. By synthesizing a series of ionone-based chalcones, we have identified a novel chalcone (17) that is a pan-antagonist of the wild type and the clinically relevant T877A, W741C and H874Y mutated ARs in luciferase reporter assays in PC-3 cells. Further, chalcone 17 demonstrates sub-micromolar to low micromolar antiproliferative activity in LNCaP, MDA-PCa-2b, 22Rv1 and C4-2B prostate cancer cells, all of which express mutated ARs and confer resistance to the current clinically used antiandrogens. The results suggest that chalcone 17 could be a good candidate for further pre-clinical development as a novel antiandrogen for advanced prostate cancer.
前列腺癌进展中的一个关键事件是从激素敏感状态转变为致命的化疗抵抗疾病状态。由于雄激素受体(AR)突变导致的拮抗剂向激动剂的转换是当前临床使用的抗雄激素药物面临的一个重大问题。我们的目标是发现新型抗雄激素药物,即使在突变型AR中也能保持纯粹的拮抗作用。通过合成一系列基于紫罗兰酮的查耳酮,我们鉴定出一种新型查耳酮(17),在PC-3细胞中的荧光素酶报告基因检测中,它能对野生型以及临床相关的T877A、W741C和H874Y突变型AR表现出泛拮抗剂活性。此外,查耳酮17在表达突变型AR并对抗雄激素药物产生耐药性的LNCaP、MDA-PCa-2b、22Rv1和C4-2B前列腺癌细胞中表现出亚微摩尔至低微摩尔的抗增殖活性。这些结果表明,查耳酮17可能是一个很好的候选药物,值得进一步进行临床前开发,作为晚期前列腺癌的新型抗雄激素药物。